Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Shionogi’s COVID-19 Pill Improves Respiratory and Feverish Symptoms
April 26, 2022
- Chugai’s Q1 Sales Double on Ronapreve Bonanza, Brisk Hemlibra Export
April 26, 2022
- Mitsubishi Tanabe’s Oral Edaravone Accepted for Swiss Review in ALS
April 26, 2022
- Janssen Files Label Expansion for Imbruvica in Japan
April 26, 2022
- Ono Seeks Japan Neoadjuvant Nod for Opdivo in NSCLC
April 26, 2022
- KM Biologics Files DTaP-IPV-Hib Vaccine in Japan
April 26, 2022
- Astellas to Write Off Massive Losses over AT132, DMD Gene Therapies
April 25, 2022
- Large-Scale Japan Trial for Shionogi Jab Confirms No Major Safety Concerns, Increase in Antibody Titers
April 25, 2022
- Investigator-Led Trial Begins for FunPep’s Antibody-Inducing Peptide
April 25, 2022
- Sumitomo to Build Cell Processing Center in US, Completion Set for FY2023
April 25, 2022
- Kowa Bags Japan Marketing Rights for Teikoku Seiyaku’s Donepezil Tape
April 22, 2022
- Hisamitsu Files Palmar Hyperhidrosis Drug in Japan, Eyes Approval in FY2023
April 22, 2022
- MSD Japan’s Sales Surge 7.5% in 2021, 1.5% Growth If Lagevrio Excluded: President
April 22, 2022
- Sumitomo Expects Further Growth for Latuda, Lonasen; Recognition by Physicians Holds Key: Sales Chief
April 22, 2022
- KM Biologics to Soon Begin Pediatric PII/III for COVID Jab, 1st Japan Trial to Include Kids below Age 5
April 21, 2022
- Novo Japan’s Sales Hit 100 Billion Yen Mark in 2021, but President Frets Future Investments
April 21, 2022
- KM Biologics to File COVID-19 Vaccine as Early as September, Chancing Emergency Approval
April 21, 2022
- GSK Japan Chief Has High Hopes for Shingrix, Blenrep, RSV Jab as Future Growth Drivers
April 21, 2022
- Lumakras, Bimzelx, Pivlaz Now Available in Japan
April 21, 2022
- Asahi Kasei Snaps Up Bionova, US CDMO for Next-Gen Antibody Drugs
April 20, 2022
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…